Search clinical trials for: BMS-754807

Total 3173 results

Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Neoplasms

Japan
Bristol-Myers Squibb

Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Neoplasms | Solid Tumors | Metastases

Australia
Bristol-Myers Squibb

Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Korea, Republic of, Canada, Australia
Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
Bristol-Myers Squibb

Completed

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin (NHV)

Healthy Volunteers

Australia
Bristol-Myers Squibb

Completed

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Breast Cancer

Australia, Hungary, Canada, United Kingdom, Belgium
Bristol-Myers Squibb
Mayo Clinic

Terminated

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Breast Cancer

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients

Healthy | Asthma

United Kingdom
Bristol-Myers Squibb

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Immunology

United States
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Alkahest, Inc.

Completed

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions

Healthy

Germany
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
China National Center for Cardiovascular Diseases
Peking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...

Unknown

A New Classification and Interventional Therapy for Coronary Artery Ectasia (NCIPCAE)

Coronary Artery Ectasia

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Netherlands, Peru, Poland, Portuga... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, United Kingdom, Korea, Republic of, Israel, Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States, United Kingdom
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
Pliant Therapeutics, Inc.

Completed

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Belgium, Australia, Netherlands, Canada, Italy, New Zealand
Pliant Therapeutics, Inc.

Completed

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) (PLN-74809)

Idiopathic Pulmonary Fibrosis

United States
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Ulcerative Colitis

United States
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Healthy Male Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Bristol-Myers Squibb

Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Mexico, Australia, Colombia, Chile, Peru
Bristol-Myers Squibb

Terminated

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Diabetic Kidney Disease

United States, Canada, Denmark, France
Pliant Therapeutics, Inc.
Stanford University

Completed

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ (IPF-201)

Idiopathic Pulmonary Fibrosis

United States
Pliant Therapeutics, Inc.

Recruiting

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Australia, Taiwan, Korea, Republic of, New Zealand, Canada, Chile, Israel
Pliant Therapeutics, Inc.

Terminated

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

Acute Respiratory Distress Syndrome | SARS-CoV-2

United States
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Recruiting

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Lupus

United States, Argentina, Germany, Mexico, Poland, Romania, Bulgaria, Spain
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Completed

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

France, Sweden, United States, Germany, Canada
Bristol-Myers Squibb

Completed

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Depression

Japan
Bristol-Myers Squibb

Terminated

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Healthy Participants | Primary Sjögren's Syndrome

Germany, United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Healthy Participants

United States
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Hematologic Cancer

Refractory Hematologic Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid... and other conditions

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Terminated

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

United States, Canada

3

Subscribe